IL-37 Ameliorates Renal Fibrosis by Restoring CPT1A-Mediated Fatty Acid Oxidation in Diabetic Kidney Disease
暂无分享,去创建一个
Jinghong Zhao | T. Xiao | Ting He | Chi Liu | Bo Zhang | Lingyi Xiong | Yaqin Wang | Shaozong Qin | Wang Xin | Li Ran
[1] Xiaoyan Tang,et al. Rhein Improves Renal Fibrosis by Restoring Cpt1a-Mediated Fatty Acid Oxidation through SirT1/STAT3/twist1 Pathway , 2022, Molecules.
[2] A. Sendelhofert,et al. Expression of IL-37 Correlates With Immune Cell Infiltrate and Fibrosis in Pediatric Autoimmune Liver Diseases , 2022, Journal of pediatric gastroenterology and nutrition.
[3] G. Ding,et al. Transition of acute kidney injury to chronic kidney disease: role of metabolic reprogramming. , 2022, Metabolism: clinical and experimental.
[4] Avi Ma’ayan,et al. Loss of proximal tubular transcription factor Krüppel-like factor 15 exacerbates kidney injury through loss of fatty acid oxidation. , 2021, Kidney international.
[5] Y. Gan,et al. Pharmaceutical targeting of succinate dehydrogenase in fibroblasts controls bleomycin-induced lung fibrosis , 2021, Redox biology.
[6] N. Samsu. Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment , 2021, BioMed research international.
[7] Rong Zheng,et al. Update on the Mechanisms of Tubular Cell Injury in Diabetic Kidney Disease , 2021, Frontiers in Medicine.
[8] H. Tilg,et al. Modulation of Liver Inflammation and Fibrosis by Interleukin-37 , 2021, Frontiers in Immunology.
[9] D. Serra,et al. Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis. , 2021, The Journal of clinical investigation.
[10] Jie Du,et al. Role of the CTRP6/AMPK pathway in kidney fibrosis through the promotion of fatty acid oxidation. , 2020, European journal of pharmacology.
[11] Yi Fu,et al. Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism. , 2020, Cell metabolism.
[12] Daohai Zhang,et al. IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4 , 2020, Nature Communications.
[13] Kyung Lee,et al. Diabetic Kidney Disease: Challenges, Advances, and Opportunities , 2020, Kidney Diseases.
[14] Hee-Seong Jang,et al. Defective Mitochondrial Fatty Acid Oxidation and Lipotoxicity in Kidney Diseases , 2020, Frontiers in Medicine.
[15] S. Park,et al. IL-37 Attenuates Lung Fibrosis by Inducing Autophagy and Regulating TGF-β1 Production in Mice , 2019, The Journal of Immunology.
[16] Jun Gu,et al. Klotho inhibits PKCα/p66SHC-mediated podocyte injury in diabetic nephropathy , 2019, Molecular and Cellular Endocrinology.
[17] P. Conti,et al. Mast Cells May Regulate The Anti-Inflammatory Activity of IL-37 , 2019, International journal of molecular sciences.
[18] D. Seals,et al. Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue , 2018, The Journal of Biological Chemistry.
[19] Xianli Yuan,et al. Interleukin-37 Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice , 2018, Inflammation.
[20] H. Chung,et al. Impairment of PPARα and the Fatty Acid Oxidation Pathway Aggravates Renal Fibrosis during Aging. , 2018, Journal of the American Society of Nephrology : JASN.
[21] G. Cavalli,et al. Suppression of inflammation and acquired immunity by IL‐37 , 2018, Immunological reviews.
[22] P. Bhargava,et al. Mitochondrial energetics in the kidney , 2017, Nature Reviews Nephrology.
[23] M. Ghaly,et al. Serum Interleukin‐37: a new player in Lupus Nephritis? , 2017, International journal of rheumatic diseases.
[24] R. Gilbert. Proximal Tubulopathy: Prime Mover and Key Therapeutic Target in Diabetic Kidney Disease , 2017, Diabetes.
[25] Yili Wang,et al. IL-37 mediates the antitumor activity in renal cell carcinoma , 2015, Medical Oncology.
[26] N. Robles,et al. Non-Proteinuric Diabetic Nephropathy , 2015, Journal of clinical medicine.
[27] J. Whisstock,et al. IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction , 2015, Nature Immunology.
[28] B. Palmer,et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8 , 2015, Proceedings of the National Academy of Sciences.
[29] A. Jevnikar,et al. IL-37 inhibits IL-18-induced tubular epithelial cell expression of pro-inflammatory cytokines and renal ischemia-reperfusion injury. , 2015, Kidney international.
[30] Kumar Sharma,et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development , 2014, Nature Medicine.
[31] H. Tilg,et al. IL-37 protects against obesity-induced inflammation and insulin resistance , 2014, Nature Communications.
[32] C. Dinarello,et al. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses , 2014, Proceedings of the National Academy of Sciences.
[33] M. Febbraio,et al. Interleukin-18 Activates Skeletal Muscle AMPK and Reduces Weight Gain and Insulin Resistance in Mice , 2013, Diabetes.
[34] S. Bakker,et al. Glomerular and Tubular Damage Markers Are Elevated in Patients With Diabetes , 2011, Diabetes Care.
[35] Jai Radhakrishnan,et al. Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[36] Sheetal Sharma,et al. The IL-1 Family Member 7b Translocates to the Nucleus and Down-Regulates Proinflammatory Cytokines1 , 2008, The Journal of Immunology.
[37] E. Neilson,et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. , 2002, The Journal of clinical investigation.
[38] M. Cooper,et al. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? , 1999, Kidney international.
[39] R. Atkins,et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. , 2004, Kidney international.